Predicting Parkinson's disease - why, when, and how?
Identifieur interne : 000E05 ( PubMed/Checkpoint ); précédent : 000E04; suivant : 000E06Predicting Parkinson's disease - why, when, and how?
Auteurs : R B Postuma [Canada] ; J. MontplaisirSource :
- Parkinsonism & related disorders [ 1873-5126 ] ; 2009.
English descriptors
- KwdEn :
- Autonomic Nervous System Diseases (diagnosis), Autonomic Nervous System Diseases (etiology), Brain Stem (pathology), Brain Stem (physiopathology), Depression (diagnosis), Depression (etiology), Disease Progression, Humans, Olfaction Disorders (diagnosis), Olfaction Disorders (etiology), Parkinson Disease (complications), Parkinson Disease (diagnosis), Parkinson Disease (psychology), Personality, Predictive Value of Tests, Sleep Wake Disorders (diagnosis), Sleep Wake Disorders (etiology), Ultrasonography, Doppler, Transcranial (methods), Vision Disorders (diagnosis), Vision Disorders (etiology).
- MESH :
- complications : Parkinson Disease.
- diagnosis : Autonomic Nervous System Diseases, Depression, Olfaction Disorders, Parkinson Disease, Sleep Wake Disorders, Vision Disorders.
- etiology : Autonomic Nervous System Diseases, Depression, Olfaction Disorders, Sleep Wake Disorders, Vision Disorders.
- methods : Ultrasonography, Doppler, Transcranial.
- pathology : Brain Stem.
- physiopathology : Brain Stem.
- psychology : Parkinson Disease.
- Disease Progression, Humans, Personality, Predictive Value of Tests.
Abstract
Parkinson's disease (PD) is a progressive disorder with a presymptomatic interval; that is, there is a period during which the pathologic process has begun, but motor signs required for the clinical diagnosis are absent. There is considerable interest in discovering markers to diagnose this preclinical stage. Current predictive marker development stems mainly from two principles; first, that pathologic processes occur in lower brainstem regions before substantia nigra involvement and second, that redundancy and compensatory responses cause symptoms to emerge only after advanced degeneration. Decreased olfaction has recently been demonstrated to predict PD in prospective pathologic studies, although the lead time may be relatively short and the positive predictive value and specificity are low. Screening patients for depression and personality changes, autonomic symptoms, subtle motor dysfunction on quantitative testing, sleepiness and insomnia are other potential simple markers. More invasive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, transcranial ultrasound, and dopaminergic functional imaging may be especially useful in those at high risk or for further defining risk in those identified through primary screening. Despite intriguing leads, direct testing of preclinical markers has been limited, mainly because there is no reliable way to identify preclinical disease. Idiopathic RBD is characterized by loss of normal atonia with REM sleep. Approximately 50% of affected individuals will develop PD or dementia within 10 years. This provides an unprecedented opportunity to test potential predictive markers before clinical disease onset. The results of marker testing in idiopathic RBD with its implications for disease prediction will be detailed.
DOI: 10.1016/S1353-8020(09)70793-X
PubMed: 20082967
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:20082967Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predicting Parkinson's disease - why, when, and how?</title><author><name sortKey="Postuma, R B" sort="Postuma, R B" uniqKey="Postuma R" first="R B" last="Postuma">R B Postuma</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada. ronald.postuma@mcgill.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Montplaisir, J" sort="Montplaisir, J" uniqKey="Montplaisir J" first="J" last="Montplaisir">J. Montplaisir</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="RBID">pubmed:20082967</idno><idno type="pmid">20082967</idno><idno type="doi">10.1016/S1353-8020(09)70793-X</idno><idno type="wicri:Area/PubMed/Corpus">000E16</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000E16</idno><idno type="wicri:Area/PubMed/Curation">000E16</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000E16</idno><idno type="wicri:Area/PubMed/Checkpoint">000E16</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000E16</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Predicting Parkinson's disease - why, when, and how?</title><author><name sortKey="Postuma, R B" sort="Postuma, R B" uniqKey="Postuma R" first="R B" last="Postuma">R B Postuma</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada. ronald.postuma@mcgill.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec</wicri:regionArea><orgName type="university">Université McGill</orgName><placeName><settlement type="city">Montréal</settlement><region type="state">Québec</region></placeName></affiliation></author><author><name sortKey="Montplaisir, J" sort="Montplaisir, J" uniqKey="Montplaisir J" first="J" last="Montplaisir">J. Montplaisir</name></author></analytic><series><title level="j">Parkinsonism & related disorders</title><idno type="eISSN">1873-5126</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Autonomic Nervous System Diseases (diagnosis)</term><term>Autonomic Nervous System Diseases (etiology)</term><term>Brain Stem (pathology)</term><term>Brain Stem (physiopathology)</term><term>Depression (diagnosis)</term><term>Depression (etiology)</term><term>Disease Progression</term><term>Humans</term><term>Olfaction Disorders (diagnosis)</term><term>Olfaction Disorders (etiology)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (psychology)</term><term>Personality</term><term>Predictive Value of Tests</term><term>Sleep Wake Disorders (diagnosis)</term><term>Sleep Wake Disorders (etiology)</term><term>Ultrasonography, Doppler, Transcranial (methods)</term><term>Vision Disorders (diagnosis)</term><term>Vision Disorders (etiology)</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Depression</term><term>Olfaction Disorders</term><term>Parkinson Disease</term><term>Sleep Wake Disorders</term><term>Vision Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Autonomic Nervous System Diseases</term><term>Depression</term><term>Olfaction Disorders</term><term>Sleep Wake Disorders</term><term>Vision Disorders</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Ultrasonography, Doppler, Transcranial</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain Stem</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain Stem</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Disease Progression</term><term>Humans</term><term>Personality</term><term>Predictive Value of Tests</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Parkinson's disease (PD) is a progressive disorder with a presymptomatic interval; that is, there is a period during which the pathologic process has begun, but motor signs required for the clinical diagnosis are absent. There is considerable interest in discovering markers to diagnose this preclinical stage. Current predictive marker development stems mainly from two principles; first, that pathologic processes occur in lower brainstem regions before substantia nigra involvement and second, that redundancy and compensatory responses cause symptoms to emerge only after advanced degeneration. Decreased olfaction has recently been demonstrated to predict PD in prospective pathologic studies, although the lead time may be relatively short and the positive predictive value and specificity are low. Screening patients for depression and personality changes, autonomic symptoms, subtle motor dysfunction on quantitative testing, sleepiness and insomnia are other potential simple markers. More invasive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, transcranial ultrasound, and dopaminergic functional imaging may be especially useful in those at high risk or for further defining risk in those identified through primary screening. Despite intriguing leads, direct testing of preclinical markers has been limited, mainly because there is no reliable way to identify preclinical disease. Idiopathic RBD is characterized by loss of normal atonia with REM sleep. Approximately 50% of affected individuals will develop PD or dementia within 10 years. This provides an unprecedented opportunity to test potential predictive markers before clinical disease onset. The results of marker testing in idiopathic RBD with its implications for disease prediction will be detailed.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20082967</PMID><DateCreated><Year>2010</Year><Month>01</Month><Day>19</Day></DateCreated><DateCompleted><Year>2010</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1873-5126</ISSN><JournalIssue CitedMedium="Internet"><Volume>15 Suppl 3</Volume><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Parkinsonism & related disorders</Title><ISOAbbreviation>Parkinsonism Relat. Disord.</ISOAbbreviation></Journal><ArticleTitle>Predicting Parkinson's disease - why, when, and how?</ArticleTitle><Pagination><MedlinePgn>S105-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1353-8020(09)70793-X</ELocationID><Abstract><AbstractText>Parkinson's disease (PD) is a progressive disorder with a presymptomatic interval; that is, there is a period during which the pathologic process has begun, but motor signs required for the clinical diagnosis are absent. There is considerable interest in discovering markers to diagnose this preclinical stage. Current predictive marker development stems mainly from two principles; first, that pathologic processes occur in lower brainstem regions before substantia nigra involvement and second, that redundancy and compensatory responses cause symptoms to emerge only after advanced degeneration. Decreased olfaction has recently been demonstrated to predict PD in prospective pathologic studies, although the lead time may be relatively short and the positive predictive value and specificity are low. Screening patients for depression and personality changes, autonomic symptoms, subtle motor dysfunction on quantitative testing, sleepiness and insomnia are other potential simple markers. More invasive measures such as detailed autonomic testing, cardiac MIBG-scintigraphy, transcranial ultrasound, and dopaminergic functional imaging may be especially useful in those at high risk or for further defining risk in those identified through primary screening. Despite intriguing leads, direct testing of preclinical markers has been limited, mainly because there is no reliable way to identify preclinical disease. Idiopathic RBD is characterized by loss of normal atonia with REM sleep. Approximately 50% of affected individuals will develop PD or dementia within 10 years. This provides an unprecedented opportunity to test potential predictive markers before clinical disease onset. The results of marker testing in idiopathic RBD with its implications for disease prediction will be detailed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Postuma</LastName><ForeName>R B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada. ronald.postuma@mcgill.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montplaisir</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Parkinsonism Relat Disord</MedlineTA><NlmUniqueID>9513583</NlmUniqueID><ISSNLinking>1353-8020</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001342" MajorTopicYN="N">Autonomic Nervous System Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001933" MajorTopicYN="N">Brain Stem</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="N">Olfaction Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017585" MajorTopicYN="N">Ultrasonography, Doppler, Transcranial</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014786" MajorTopicYN="N">Vision Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>65</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>1</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20082967</ArticleId><ArticleId IdType="pii">S1353-8020(09)70793-X</ArticleId><ArticleId IdType="doi">10.1016/S1353-8020(09)70793-X</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country><region><li>Québec</li></region><settlement><li>Montréal</li></settlement><orgName><li>Université McGill</li></orgName></list><tree><noCountry><name sortKey="Montplaisir, J" sort="Montplaisir, J" uniqKey="Montplaisir J" first="J" last="Montplaisir">J. Montplaisir</name></noCountry><country name="Canada"><region name="Québec"><name sortKey="Postuma, R B" sort="Postuma, R B" uniqKey="Postuma R" first="R B" last="Postuma">R B Postuma</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000E05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:20082967
|texte= Predicting Parkinson's disease - why, when, and how?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:20082967" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |